Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111662 | 0.86 | HTR6 (0.45) | HTR6DRD2HTR2AHTR7 | |
| SCHEMBL6099557 | 0.84 | KMT2A (0.43) | HTR6 | |
| SCHEMBL6110763 | 0.78 | HTR6 (0.46) | HTR6GSK3BDRD2HTR2AHTR7 | |
| SCHEMBL6805163 | 0.76 | HTR6 (0.45) | HTR6AKR1C3AKR1C1CYP3A4CYP2D6 | |
| SCHEMBL6097509 | 0.69 | GAA (0.46) | HTR6HTR2AHTR1A | |
| SCHEMBL6097471 | 0.69 | DYRK1A (0.53) | HTR6DYRK1AGSK3BHTR7HTR1A | |
| SCHEMBL6098330 | 0.68 | L3MBTL1 (0.62) | HTR6DRD2HTR2AHTR7 | |
| SCHEMBL6099550 | 0.68 | HTR6 (0.46) | HTR6HTR7HTR1A | |
| SCHEMBL6100350 | 0.68 | CREBBP (0.38) | DYRK1AGSK3B | |
| SCHEMBL6097111 | 0.68 | HTR6 (0.47) | HTR6GSK3BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | HTR6 765/4885DYRK1A 1708/4885GSK3B 388/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | HTR6 883/4885DYRK1A 1847/4885GSK3B 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.